C83.19
Mantle cell lymphoma, extranodal and solid organ sites
Clinical Classification Guidelines
Medical Intelligence & Overview
Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma characterized by the growth of cancerous B cells in the lymphatic system. This disease often affects lymph nodes but can also spread to extranodal sites such as the gastrointestinal tract, bone marrow, and other solid organs. The ICD-10 code C83.19 specifically designates cases where MCL has spread beyond lymph nodes to extranodal and solid organ sites, indicating a more advanced stage of the disease. Recognizing this condition is important for appropriate management and understanding the disease’s progression.
Causes & Symptoms
Clinical Causes: Genetic mutations leading to abnormal B cell growth Age-related changes in immune function Exposure to certain environmental toxins (though less common) No clear cause identified in most cases
Key Symptoms: Swelling or lumps in lymph nodes, often painless Persistent fatigue and weakness Unexplained weight loss Night sweats Fever without an infection Abdominal pain or fullness due to organ involvement Unexplained infections due to weakened immune system Symptoms related to specific areas of extranodal spread, such as gastrointestinal symptoms if the GI tract is involved
Diagnostic & Treatment
Diagnosis Path: Medical history review and physical examination focusing on lymph node enlargement and possible extranodal sites Imaging studies such as CT scans, PET scans, or MRI to assess the extent of spread Biopsy of affected tissue (lymph node or extranodal sites) to examine the cancer cells under a microscope Immunophenotyping tests to verify cell markers characteristic of mantle cell lymphoma Bone marrow biopsy to check for marrow involvement Laboratory tests, including blood counts and other blood tests to evaluate overall health
Treatment Protocols: Chemotherapy regimens to kill cancer cells and reduce tumor burden Targeted therapy, such as medications that specifically target cancer cell growth pathways (e.g., BTK inhibitors) Immunotherapy approaches to stimulate the immune system against lymphoma cells Radiation therapy for localized or palliative purposes Stem cell or bone marrow transplants may be considered in suitable candidates Supportive care to manage symptoms and maintain quality of life, including blood transfusions or antibiotics
Clinical Advice & FAQs
Billing Guidance
Is C83.19 a billable ICD-10 code?
Yes, C83.19 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C83.19?
Clinical documentation must specify the nature of Mantle cell lymphoma, extranodal and solid organ sites and any associated comorbidities for accurate reporting.
Cite this Clinical Reference